Featured Research

from universities, journals, and other organizations

Listening In On The Whispering Heart

Date:
August 16, 2004
Source:
Institute Of Physics
Summary:
A new implantable device that could send an early-warning signal to your doctor before heart rhythm problems arise, may now be possible thanks to research described in the latest issue of the Institute of Physics journal, Physiological Measurement.

A new implantable device that could send an early-warning signal to your doctor before heart rhythm problems arise, may now be possible thanks to research described in the latest issue of the Institute of Physics journal, Physiological Measurement.

More than five million people worldwide have been diagnosed with the heart disorder atrial fibrillation (AF). In AF, the upper chambers of the heart, the atria, quiver and beat rapidly: a condition that can often lead to heart failure and stroke, making AF a major cause of hospital admission. Similarly, another disorder of the heart's rhythm, ventricular fibrillation (VF) can be just as bad for your health. Biomedical engineer Kityee Au-Yeung of Duke University, in North Carolina, says there is an urgent need to find a safe and effective treatment for AF.

Au-Yeung and her colleagues Chad Johnson and Patrick Wolf, have now developed an implantable electronic device that could help doctors listen in to the whispering heart, and prevent serious attacks of AF before it happens.

AF can often be stopped by a short, sharp electrical shock to the heart, a method known as electrical cardioversion, or defibrillation, a method familiar to anyone who watches TV hospital dramas. The method is designed to resynchronize the heart beat and restore its normal rhythm. Cardioversion is very successful in stopping an AF or VF episode and there are calls for the installation of defibrillators in many public places. But, the electrical shocks delivered to the patient can be very painful.

"AF is not an immediately life-threatening condition, and does not require immediate attention like VF does," explains Au-Yeung, "Defibrillating an AF episode, if not done properly, could itself lead to a fatal ventricular arrhythmia."

Au-Yeung and her colleagues are investigating a new version of electrical defibrillation that uses lower energy shocks, which they say would be far less painful for the patient as well as carrying less risk of complications. "We want to determine if AF can be terminated by using a series of lower energy electrical shocks, instead of a single high energy one," explain Au-Yeung, who is a graduate researcher in Wolf's laboratory at Duke.

To test the concept the team has designed and built a device that can be implanted under the skin close to the heart, like a pacemaker. Sensors on the implantable cardiac telemetry system pick up the heart's electrical pattern and send out a continuous radio signal, which is picked up by a notebook computer fitted with a receiver. With this set up, the researchers could record an electrocardiogram directly on to the computer without the need for external sensors and wiring.

This is not a one-way system though. The computer can send a signal back to the device telling it to deliver a short burst of electrical pulses directly to the heart. The sensors measure the effect on the heartbeat and send the information straight back to the computer. "We hope that with this novel system, we can learn more about AF and subsequently, find a more effective way to treat it," Au-Yeung says.

"A version of this device would most likely be targeted at patients who have already been implanted with a pacemaker or an ICD (implantable cardioverter defibrillator)," adds Au-Yeung, "For example, the remote monitoring and low energy pacing techniques could be incorporated into a pacemaker design." Remote monitoring from a patient's home could alert their doctor to an AF episode and the doctor could then administer appropriate pacing therapy and monitor its effects.


Story Source:

The above story is based on materials provided by Institute Of Physics. Note: Materials may be edited for content and length.


Cite This Page:

Institute Of Physics. "Listening In On The Whispering Heart." ScienceDaily. ScienceDaily, 16 August 2004. <www.sciencedaily.com/releases/2004/08/040815232121.htm>.
Institute Of Physics. (2004, August 16). Listening In On The Whispering Heart. ScienceDaily. Retrieved July 22, 2014 from www.sciencedaily.com/releases/2004/08/040815232121.htm
Institute Of Physics. "Listening In On The Whispering Heart." ScienceDaily. www.sciencedaily.com/releases/2004/08/040815232121.htm (accessed July 22, 2014).

Share This




More Health & Medicine News

Tuesday, July 22, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins